Wall Street Zen Downgrades Amgen (NASDAQ:AMGN) to Hold

Key Points

• Wall Street Zen downgraded Amgen (NASDAQ:AMGN) from a "buy" to a "hold" in a report released Saturday.
• Analyst coverage is mixed but leans neutral: Amgen's consensus is an average rating of "Hold" with an average target price of $356.62 (1 Strong Buy, 14 Buy, 14 Hold, 2 Sell).
• Fundamentals remain solid—Amgen beat quarterly estimates (EPS $5.29 vs. $4.76; revenue $9.87B), set FY2026 guidance of 21.600–23.000 EPS, and currently trades around $344.55 with a market cap of ~$186B and a P/E of 24.21.

Amgen (NASDAQ:AMGN - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

Several other research firms have also commented on AMGN. UBS Group boosted their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. Morgan Stanley upped their target price on shares of Amgen from $309.00 to $326.00 and gave the stock an "equal weight" rating in a research note on Friday, April 10th. Daiwa Securities Group upped their target price on shares of Amgen from $370.00 to $410.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 10th. Wells Fargo & Company upped their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 19th. Finally, TD Cowen reiterated a "buy" rating on shares of Amgen in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Amgen currently has an average rating of "Hold" and an average target price of $356.62.

Amgen Trading Down 1.2%

NASDAQ:AMGN opened at $344.55 on Friday. Amgen has a one year low of $261.43 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company's 50-day simple moving average is $360.74 and its 200 day simple moving average is $339.15. The firm has a market capitalization of $185.95 billion, a P/E ratio of 24.21, a PEG ratio of 3.64 and a beta of 0.47.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the firm posted $5.31 earnings per share. Amgen's quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts forecast that Amgen will post 22.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Dogwood Wealth Management LLC increased its stake in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Anfield Capital Management LLC increased its stake in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after purchasing an additional 70 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the fourth quarter worth $26,000. Tower View Wealth Management LLC increased its stake in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after purchasing an additional 63 shares in the last quarter. Finally, Manning & Napier Advisors LLC increased its stake in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after purchasing an additional 32 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported completion of an early Phase 1/2 MTAP‑null cancer combination study — a clinical milestone that can de‑risk a development program and supports longer‑term oncology pipeline value. Company Study Completion
• Positive Sentiment: Guggenheim nudged its price target on AMGN to $351 (maintaining a Neutral rating), which signals modest analyst upside versus the stock’s trading range and can provide short‑term support. Guggenheim PT Update
• Neutral Sentiment: Amgen confirmed it will report Q1 2026 results after the market close on April 30 and will host a webcast — an obvious near‑term volatility driver as investors adjust positions into the print. Q1 Webcast
• Neutral Sentiment: Legislation (H.R. 8203) expanding workforce and treatment funding for substance use disorders was introduced; Amgen is listed among relevant healthcare companies — this is a longer‑horizon policy item that could modestly affect labor/training dynamics but is unlikely to move the stock immediately. H.R.8203 Bill
• Negative Sentiment: Pre‑earnings previews from Zacks and Yahoo Finance suggest AMGN may report a decline in Q1 earnings (reducing the odds of an earnings beat), which increases downside risk into the report. Earnings Preview
• Negative Sentiment: Insiders sold roughly US$4.1M of Amgen stock over the past year — sizable insider selling can be perceived as a cautionary signal by some investors. Insider Selling
• Neutral Sentiment: Amgen announced the planned retirement of EVP & Chief Technology Officer David M. Reese effective June 30, 2026, with a strategic leadership realignment — a governance event to watch, but presented as orderly and planned. CTO Retirement

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.